Ania Jastreboff
Endocrinology, Diabetes & Metabolism · New Haven, CTNPI 1780788349
Payments from drug & device makers
Across 1,393 payments — averaging $1599.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1.2M
- Novo Nordisk AS$440K
- Boehringer Ingelheim$200K
- Amgen$115K
- Rhythm Pharmaceuticals, Inc.$89K
- Novo Nordisk$86K
- plus $110K from 15 others
Across 9 payments — averaging $5201.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$25K
- Amgen$21K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 285 | $1,188,341 |
| Novo Nordisk AS | 724 | $440,028 |
| Boehringer Ingelheim | 52 | $199,918 |
| Amgen | 17 | $114,601 |
| Rhythm Pharmaceuticals, Inc. | 64 | $88,723 |
| Novo Nordisk | 77 | $86,241 |
| Boehringer Ingelheim International GmbH | 120 | $43,840 |
| Lilly USA, LLC | 11 | $15,689 |
| Zealand Pharma A/s | 6 | $14,048 |
| Regeneron | 11 | $10,973 |
| Pfizer | 4 | $7,300 |
| F. Hoffmann-la Roche AG | 4 | $6,254 |
| Astrazeneca UK Limited | 4 | $4,115 |
| AstraZeneca | 5 | $4,028 |
| Astrazeneca AB | 3 | $2,160 |
| Novo Nordisk Health Care AG | 1 | $1,360 |
| Zealand Pharma US, Inc. | 1 | $189 |
| Medtronic | 1 | $94 |
| Covidien LP | 1 | $81 |
| Corcept Therapeutics | 1 | $50 |
| Johnson & Johnson | 1 | $48 |
How this compares
$2,228,079 in reported general payments places this provider in the 95th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in New Haven
- Gerald ShulmanNew Haven$1M
- Karl InsognaNew Haven$903K
- Clemens BergwitzNew Haven$735K
- Silvio InzucchiNew Haven$461K
- Francis WilsonNew Haven$415K
- Philip GoldbergNew Haven$324K
- Kevan HeroldNew Haven$309K
- Richard KibbeyNew Haven$284K
- Robert SherwinNew Haven$280K
- Raimund HerzogNew Haven$221K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.